Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • BW TV
  • Subscribe to Print

Latest Articles in novartis

Can We Afford This Wave?

People too are tired of all the restrictions, the loss of wages, loss of esteem and fatigue. More than 50% of the cases have originated in Maharashtra and its cities, defying normal logic.

Read More

Novartis Arthritis Drug Fails To Help COVID-19 Patients

The medicine, approved as Ilaris for juvenile arthritis and other conditions, also did not meet its key secondary endpoint of reducing COVID-19 mortality in a late-phase clinical trial

Read More

Novartis Arthritis Drug Fails To Help COVID-19 Patients

The medicine, approved as Ilaris for juvenile arthritis and other conditions, also did not meet its key secondary endpoint of reducing COVID-19 mortality in a late-phase clinical trial

Read More

Novartis Buys Vedere Bio, Whose Founders Helped Blind Mice See

Novartis is paying $150 million upfront for the U.S. biotechnology company, with the remainder in milestone payments for a total of $280 million.

Read More

Novartis Third-Quarter Core Net Income Rises To $3.47 Billion

The Basel-based company broadened its core operating income growth forecast to low double-digit to mid-teen percentage rate growth, from a low double-digit range previously, while net sales are expected to grow in the mid-single-digit percentage range.

Read More

Novartis Says Beovu Matched Rival Eylea In Visual Acuity In Eye Disease

"This data confirms our strong belief in Beovu as a potential therapy for DME patients," said Dirk Sauer, who leads Novartis Pharma Ophthalmology's drug development.

Read More

Roche Studies Ocrevus, Experimental Drug In MS As Novartis Moves In

Roche has started a late-stage clinical trial for its molecule fenebrutinib and is doing a clinical trial of higher-dose Ocrevus against relapsing MS and primary progressive MS.

Read More

Novartis Immuno-Oncology Drug Candidate Fails Skin Cancer Trial

The drug did not improve progression-free survival in previously untreated patients with BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar + Mekinist alone, Novartis said.

Read More

Novartis To Provide 'No Profit' COVID-19 Drugs To Low-Income Countries

Novartis said it would provide medicines ranging from antibiotics and steroids to diarrhea pills to 79 countries on the World Bank's list of low- and lower-middle income nations.

Read More

Japan's Takeda Expects $200 Million Operating Loss Related To Novartis' Xiidra Withdrawal

Takeda sold Xiidra to Novartis for $3.4 billion upfront and up to an additional $1.9 billion in potential milestone receipts.

Read More

Novartis, Former Unit To Pay $346 Million To Resolve US Bribery Charges

Novartis will also pay $112.8 million to settle related civil charges by the U.S. Securities and Exchange Commission.

Read More

Novartis CEO Says Any New Coronavirus Vaccine Will Take Two Years

But experts have said no vaccine is expected to be ready for use until at least 2021, as they must be widely tested in humans before being administered to hundreds of millions, if not billions, of people to prevent infection.

Read More

Novartis Wins Expanded European OK For Cosentyx Amid Pursuit Of $5 Billion Sales

European Commission (EC) approved Cosentyx for adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA), characterized by chronic back pain.

Read More

Novartis Posts First-Quarter Sales, Profit Beat As COVID-19 Spurs Prescriptions

Sales rose to $12.3 billion from $11.1 billion in the year-ago period, also above the poll average of $12 billion

Read More

Novartis To Sponsor Large Clinical Trial Of HCQ In Hospitalised COVID-19 Patients

Novartis plans to begin enrollment for this study within the next few weeks and is committed to reporting results as soon as possible.

Read More